According to the results of this study, it is suggested that PLR ≥ 143.4 (according to the best cutoff value of ROC) should be used as the screening threshold of anemia risk in MHD patients, and Hb should be monitored first in patients with high PLR and EPO dosage should be optimized. This evidence concerns the gene GSTM1 and anemia.